Keywords

• Warfarin sodium
• cas 129-06-6
• Warfarin sodium cas 129-06-6

Quick Details

• ProName: Warfarin sodium cas 129-06-6
• CasNo: 129-06-6
• Molecular Formula: C19H15NaO4
• Appearance: white powder
• Application: CHEMICAL
• DeliveryTime: within 2-3 day
• PackAge: carton boc
• Port: tianjin/qingdao/shanghai
• ProductionCapacity: 1000000 Metric Ton/Day
• Purity: 99%
• Storage: cool and dry
• Transportation: COOL AND DRY
• LimitNum: 1 Kilogram
• Grade: Industrial Grade
• 1: 100

Superiority

Chemical Name:Warfarin sodium

• CAS No.129-06-6
• Molecular Formula:C19H16NaO4
• Formula Weight:332.331

Synonyms:3-(a-Acetonylbenzyl)-4-hydroxycoumarinsodium;Aldocumar;Athrombin;Coumadin;Coumadine;Dimantil;Marevam;Orfarin;Panwarfin;Prothromadin;Simarc 2;Sodiumwarfarin;Sofarin;Tintorane;Varfine;Waran;Warfarina;Warfil 5;Zoocoumarin sodium salt;2H-1-Benzopyran-2-one,4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (9CI);Coumarin, 3-(a-acetonylbenzyl)-4-hydroxy-, sodium salt (8CI);

Details

Product Name: Warfarin Sodium clathrate
Other name: 3-(A-acetonylbenzyl)-4-Hydroxycoumarin 
Molecular formula: C19H15NaO4 
CAS No.: 129-06-6 
solubility :Very soluble in water, freely soluble in ethanol (96 per cent), soluble in acetone, very slightly soluble in methylene chloride.
Molecular weight: 330.31  
Chemical Properties: White or almost white, crystalline powder.
Uses :Vitamin K epoxide reductase inhibitor; oral anticoagulant (coumarin).
 

It is applicable to patients who need long-term continuous anticoagulation.

1. It is used to prevent and treat thromboembolic diseases, prevent the formation and development of thrombosis, such as prevention and treatment of deep vein thrombosis and thrombophlebitis, reduce the incidence rate and mortality of pulmonary embolism, and reduce the incidence of venous thrombosis in major surgery (including orthopedic surgery), rheumatic heart disease, artificial heart valve replacement, etc.

2. Auxiliary drugs for myocardial infarction, such as the treatment of atrial fibrillation with pulmonary embolism and coronary artery occlusion.